Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?

Key Takeaways Gilead expands pipeline via Ouro Medicines and Arcellx deals to boost immunology and CAR-T portfolio.GILD will add OM336 and anito-cel, with the latter seen as a key catalyst ahead of a 2026 U.S. decision.Arcellx buyout boosts margins by ending profit-sharing, while competition may pressure growth through 2026.Gilead Sciences, Inc. (GILD) is accelerating its external innovation strategy through targeted acquisitions to bolster its pipeline and diversify beyond its dominant HIV franchise.The re ...